If you need more lookups,
subscriptions start at $34 USD/month.
Brian Kaspar Location
San Diego, CA, US
Brian Kaspar Work
2021 -now Chief Scientific Officer @
2021 -now Board Member @ AccuGen Group and Vinta Bio
2021 -now Scientific Advisory Board Member and Board of Directors @
2010 -2023 Scientific Founder @
2012 -2019 Chief Scientific Officer, SVP, Scientific Founder, @ AveXis Inc., a Novartis company
2004 -2017 Professor of Pediatrics, Faculty @
1999 -2004 Research Fellow @
1998 -2004 Research Grad and Postdoctoral fellow @
Brian Kaspar Education
University of California, San Diego
University of Illinois Urbana-Champaign
Brian Kaspar Skills
Molecular Biology
Cell Biology
Neuroscience
Cell Culture
Animal Models
Immunohistochemistry
Life Sciences
Western Blotting
Science
Biochemistry
Fluorescence Microscopy
Genetics
Public Health
Teaching
Tissue Culture
PCR
Lifesciences
Confocal Microscopy
Microscopy
Higher Education
Healthcare
Clinical Research
In Vivo
Pediatrics
Statistics
Grant Writing
Hospitals
Data Analysis
Research
Biotechnology
Laboratory
Cell
Immunology
Molecular Cloning
qPCR
Protein Expression
ELISA
Flow Cytometry
Drug Discovery
Scientific Writing
Protein Purification
In Vitro
Clinical Trials
Immunofluorescence
Transfection
Assay Development
Stem Cells
RT-PCR
DNA
Polymerase Chain Reaction (PCR)
Public Speaking
Business Strategy
Polymerase Chain Reaction Pcr
Rt Pcr
Strategy
Business Development
Management
Marketing
Polymerase Chain Reaction
Brian Kaspar Summary
Brian Kaspar, based in San Diego, CA, US, is currently a Chief Scientific Officer at Insmed Incorporated. Brian Kaspar brings experience from previous roles at AccuGen Group and Vinta Bio, Endsulin, Milo Biotechnology and AveXis Inc., a Novartis company. Brian Kaspar holds a University of California, San Diego. With a robust skill set that includes Molecular Biology, Cell Biology, Neuroscience, Cell Culture, Animal Models and more. Brian Kaspar has 4 emails and 8 mobile phone numbers on RocketReach.
Looking for a different Brian Kaspar?
Find contact details for 700 million professionals.